Replies to post #312149 on Bioelectronics Corp (BIEL)

[GetSeriousOK]

Any potential buyer/merger candidate would read BIEL's financial statements and laugh out loud. It's a disposable product that experiences revenue spikes when a new product or campaign is launched, followed by significant and alarming DECREASES in revenue.

That's all the evidence an experienced biotech or biopharma needs to see.

The NOPAIN Act doesn't guarantee sales for BIEL. It doesn't even guarantee market exposure of RecoveryRx. Maybe revenues will increase in 2025 or 2026, maybe not, but nobody is going to buy this company or merge with this company until they see evidence that there's a market for this device.

The worse a pinkie biotech gets, the louder the shouting gets about a BUYOUT.

[art2426]

WOW, that is alot to hope for, for a satisfactory outcome to any possible M/A or buyout!!!
The wrench thrown in that scenario is simply, that any conglomerate that wants these products has a serious upper hand in negotiations with the financial instability of this company. These Big Boys did not get BIG being soft and stupid. The have way more negotiating power than this little company that just report dismal sales. ie they are not going to the negotiating table feeling sorry for Bioelectronics management or its shareholders. Let's face it, if they want these products they can wait until the family throws in the towel and get this VERY CHEAP. No, if the family wanted to sell, IMO they have missed the boat. With sales as such now being reported, as a stockholder I am not waiting for that dream. But believe me, I was also hoping for that for YEARS. Not anymore.

[pinhigh]

You'd be hard pressed to find a pain relief tech more suitable than Biel's for the NoPain Act. Hopefully that Act is implemented in 2024. Society needs non-opioid pain relief right now!